Sep 18, 2024 08:54AM
Aug 8, 2024 06:30AM
Aug 7, 2024 06:30AM
Aug 7, 2024 06:29AM
May 1, 2024 06:30AM
Feb 28, 2024 06:30AM
Nov 1, 2023 06:30AM G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
Oct 18, 2023 08:07AM
Oct 18, 2023 08:00AM
Sep 18, 2023 07:00AM
Sep 18, 2023 07:00AM
Aug 2, 2023 06:30AM
May 3, 2023 06:30AM
Mar 1, 2023 06:30AM G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Mar 1, 2023 06:30AM
Feb 9, 2023 08:00AM
Jan 9, 2023 06:31AM
Jan 9, 2023 06:30AM
Nov 2, 2022 06:30AM
Nov 2, 2022 06:30AM
Oct 10, 2022 06:30AM G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
Aug 3, 2022 06:30AM
Jul 25, 2022 06:31AM
Jul 25, 2022 06:30AM
Jul 13, 2022 10:16AM
Jul 13, 2022 10:15AM
Jul 13, 2022 10:15AM
Jun 13, 2022 07:00AM G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
May 20, 2022 10:30AM
May 4, 2022 06:30AM
Feb 23, 2022 06:30AM
Dec 16, 2021 06:02AM
Dec 16, 2021 06:00AM
Nov 11, 2021 07:26PM
Nov 3, 2021 06:30AM G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
Oct 7, 2021 08:00AM
Oct 1, 2021 07:45AM
Sep 15, 2021 06:46AM
Sep 15, 2021 06:45AM
Aug 4, 2021 04:01PM
Aug 4, 2021 08:00AM
Jul 19, 2021 09:21AM G1 Therapeutics (GTHX) Receives Fast Track Designation from FDA for COSELA in Combination with Chemotherapy for Treatment of Locally Advanced or Metastatic TNBC
Jul 19, 2021 09:20AM
Jun 4, 2021 09:01AM
May 17, 2021 07:00AM
May 5, 2021 04:01PM
Apr 26, 2021 09:44AM
Apr 26, 2021 09:41AM
Apr 1, 2021 07:30AM G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021
Mar 25, 2021 06:52AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All